Drug Profile
Research programme: STAT6 inhibitors - Amgen
Latest Information Update: 11 Sep 2008
Price :
$50
*
At a glance
- Originator Amgen
- Class
- Mechanism of Action Interleukin 4 inhibitors; STAT6 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 17 Aug 2004 Tularik has been acquired and merged into Amgen
- 31 Mar 2000 Preclinical development for Allergic rhinitis in USA (Unknown route)
- 31 Mar 2000 Preclinical development for Asthma in USA (Unknown route)